Bacterial News and Research

RSS

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

NICE clinical guideline for bacterial meningitis and meningococcal septicaemia in children

Every parent knows the story and every parent dreads it. You take a feverish child to the doctors, you know something isn't right; but you are just sent back home with advice about paracetamol. Hours later the child is admitted to hospital with meningitis.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Scientists find low levels of bacteria in fields sprayed with swine manure

That swine manure sprayed on to fields adds valuable nutrients to the soil is well known. But what is not known is whether all that manure is bringing harmful bacteria with it.

13 Sep 2010

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Scientists from The Scripps Research Institute have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

Oral health impacts systemic diseases: Report

It's not news that there is a significant link between one's oral health and overall health. Though studies are ongoing, researchers have known for quite some time that the mouth is connected to the rest of the body.Your mouth is the entry point of many bacteria,said Dr. Steven Grater, Pennsylvania Dental Association (PDA) member and general dentist from Harrisburg. To keep this bacteria from going into your body, cleaning your mouth (brushing, flossing and rinsing) is necessary.

13 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

Survey finds women mistreat yeast infections

Few women go through life having never suffered from the uncomfortable symptoms of a yeast infection. In fact, nearly 3 in 4 (72 percent) women will experience their first yeast infection before age 25. Furthermore, the incidence of yeast infections is highest among young women ages 18-24, who are new to the category and uncertain about symptoms and available treatment options.

10 Sep 2010

Discovery on Mycobacterium tuberculosis can offer new approaches for TB prevention

One third of the world's population is infected with Mycobacterium tuberculosis (MTB), which leads to tuberculosis (TB), a leading cause of death world-wide. A new discovery, led by a team of researchers from Case Western Reserve University School of Medicine, offers hope for new approaches to the prevention and treatment of TB. The team's discovery of a novel mechanism that may contribute to immune recognition of MTB is published in the September issue of Nature Structural and Molecular Biology.

10 Sep 2010

Advaxis receives USPTO patent for Listeria vaccine

The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.

9 Sep 2010

Multi-resistant CNS bacteria spread in Sweden hospitals

Genetically closely related skin bacteria that have developed resistance to several different antibiotics and that can cause intractable care-related infections are found and seem to be spreading within and between hospitals in Sweden.

9 Sep 2010

Insulin may reduce life-threatening bacterial infections in intensive care patients

Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study.

9 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

NIH announces award to improve human microbiome research

The National Institutes of Health today announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease.

8 Sep 2010

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0 in favor of approval for complicated skin and skin structure infections (cSSSI).

8 Sep 2010

Bacterial News and Research

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

NICE clinical guideline for bacterial meningitis and meningococcal septicaemia in children

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Excelimmune presents positive results for HRPA therapy against MRSA infections

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Scientists find low levels of bacteria in fields sprayed with swine manure

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Oral health impacts systemic diseases: Report

Numerate awarded new contract by Defense Threat Reduction Agency

Survey finds women mistreat yeast infections

Discovery on Mycobacterium tuberculosis can offer new approaches for TB prevention

Advaxis receives USPTO patent for Listeria vaccine

Multi-resistant CNS bacteria spread in Sweden hospitals

Insulin may reduce life-threatening bacterial infections in intensive care patients

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

NIH announces award to improve human microbiome research

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News